High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation

Nephrology Dialysis Transplantation

Volumn 25, Issue 8, 2010, Pages 2757-2763

  Borra, Lennaert C P ^a   Roodnat, Joke I ^a   Kal, Judith A ^a   Mathot, Ron A A ^a   Weimar, Willem ^a   Van Gelder, Teun ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

clearance; mycophenolate mofetil; pharmacokinetics; tacrolimus; variability

Indexed keywords

CREATININE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; MYCOPHENOLIC ACID;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG CLEARANCE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; GROUPS BY AGE; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; BLOOD; GRAFT REJECTION; MIDDLE AGED; PREDICTIVE VALUE; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77954779586     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq096     Document Type: Article

References (16)

1. Srinivas TR, Meier-Kriesche HU, Kaplan B. Pharmacokinetic principles of immunosuppressive drugs. Am J Transplant 2005; 5: 207-217
2. Kahan BD, Keown P, Levy GA, Johnston A. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002; 24: 330-350
3. Saint-Marcoux F, Marquet P, Jacqz-Aigrain E, Bernard N, Thirty P, Le Meur Y. Patient characteristics influencing ciclosporin pharmaco-kinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. Clin Pharmacokinet 2006; 45: 905-922
4. Van Hest RM, van Gelder T, Vulto AG, Mathot RA. Population phar- macokinetics ofmycophenolic acid in renal transplant recipients. Clin Pharmacokinet 2005; 44: 1083-1096
5. Hesselink DA, van Gelder T, van Schaik RH, Balk AH, van der Heiden IP, van Dam T. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence ofethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004; 76: 545-556
6. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynam-ics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007; 46: 13-58
7. Dansirikul C, Morris RG, Tett SE, Duffull SB. A Bayesian approach for population pharmacokinetic modelling of sirolimus. Br J Clin Pharmacol 2006; 62: 420-434
8. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynam-ics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43: 623-653
9. Djebli N, Rousseau A, Hoizey G, Rerolle JP, Toupance O, Le Meur Y. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. Clin Pharmacokinet 2006; 45: 1135-1148
10. Budde K, Glander P. Pharmacokinetic principles of immunosuppres-sive drugs. Ann Transplant 2008; 13: 5-10
11. Kahan BD, Welsh M, Urbauer DL et al. Low intraindividual variability of cyclosporin A exposure reduces chronic rejection incidence and health care costs. J Am Soc Nephrol 2000; 11: 1122-1131
12. Joosten SA, van Kooten C, Sijpkens YW, de Fijter JW, Pail LC. The pathobiology of chronic allograft nephropathy: immune-mediated damage and accelerated aging. Kidney Int 2004; 65: 1556-1559
13. West-Thielke P, Kaplan B. Therapeutic monitoring of mycophenolic acid: is there clinical utility? Am J Transplant 2007; 7: 2441-2442
14. Kahan B. High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection. Transpl Proc 1998; 30: 1639-1641
15. Kahan BD, Dunn J, Fitts C, Van Buren D, Wombolt D, Pollak R. Reduced inter- and intrasubject variability in cyclosporine pharmacoki-netics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995; 59: 505-511
16. Hesse CJ, Baan CC, Balk AH, Metselaar HJ, Weimar W, van Gelder T. Evaluation of the new EMIT enzyme immunoassay for the determination ofwhole-blood tacrolimus concentrations in kidney, heart, and liver transplant recipients. Transplant Proc 2002; 34:2988-2990